Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Downgraded by Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) from a hold rating to a sell rating in a research report released on Monday, Zacks.com reports.

According to Zacks, “Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company’s principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California. “

Other equities analysts have also issued reports about the company. LADENBURG THALM/SH SH reiterated a buy rating and issued a $9.00 price objective on shares of Armata Pharmaceuticals in a research report on Monday, July 15th. HC Wainwright reiterated a buy rating and issued a $7.00 price objective on shares of Armata Pharmaceuticals in a research report on Thursday, August 15th.

Shares of ARMP opened at $4.65 on Monday. Armata Pharmaceuticals has a 52-week low of $2.10 and a 52-week high of $19.18.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.40).

An institutional investor recently bought a new position in Armata Pharmaceuticals stock. BlackRock Inc. bought a new position in shares of Armata Pharmaceuticals Inc (NYSEAMERICAN:ARMP) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 11,264 shares of the company’s stock, valued at approximately $45,000. BlackRock Inc. owned about 0.47% of Armata Pharmaceuticals at the end of the most recent quarter.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains.

Featured Story: Stochastic Momentum Index (SMI)

Get a free copy of the Zacks research report on Armata Pharmaceuticals (ARMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

AGNC Investment Corp. Declares Aug 19 Dividend of $0.16
AGNC Investment Corp. Declares Aug 19 Dividend of $0.16
Mincon Group PLC  to Issue €0.01 Dividend
Mincon Group PLC to Issue €0.01 Dividend
Capital Investment Advisory Services LLC Acquires 27,426 Shares of SPDR S TR/SPDR BLOOMBERG BARC
Capital Investment Advisory Services LLC Acquires 27,426 Shares of SPDR S TR/SPDR BLOOMBERG BARC
REA Group Limited to Issue Final Dividend of $0.63
REA Group Limited to Issue Final Dividend of $0.63
TransGlobe Energy Co. Declares Dividend of $0.04
TransGlobe Energy Co. Declares Dividend of $0.04
Chesapeake Asset Management LLC Sells 147 Shares of Exxon Mobil Co.
Chesapeake Asset Management LLC Sells 147 Shares of Exxon Mobil Co.


© 2006-2019 Ticker Report